NEVVI Medicare utilization intelligence
or

← back

Provider profile

COLE, SCOTT MD

Medical Oncology · NPI 1346351004 · TULSA, OK

2
Groups
100
Codes · 2024
163,987
Disclosed services

COLE, SCOTT is a Medical Oncology in TULSA, OK, a member of 2 medical groups, who billed 100 distinct codes to Medicare Part B in 2024.

Groups: OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC (TULSA, OK) · STILLWATER MEDICAL CENTER AUTHORITY (STILLWATER, OK) — member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

163,987
disclosed services
100
codes billed to Medicare Part B
Prior year · CY2023 150,769 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J9299 Injection, nivolumab, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J1627 Injection, granisetron, extended-release, 0.1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9263 Injection, oxaliplatin, 0.5 mg
J0185 Injection, aprepitant, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1453 Injection, fosaprepitant, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J1930 Injection, lanreotide, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
84100 Phosphate level
83615 Lactate dehydrogenase (enzyme) level
84550 Uric acid level, blood
83735 Magnesium level
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J9173 Injection, durvalumab, 10 mg
J1434 Injection, fosaprepitant (focinvez), 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J9171 Injection, docetaxel, 1 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
J9041 Injection, bortezomib, 0.1 mg
36415 Insertion of needle into vein for collection of blood sample
J0897 Injection, denosumab, 1 mg
J0461 Injection, atropine sulfate, 0.01 mg
J0640 Injection, leucovorin calcium, per 50 mg
J2469 Injection, palonosetron hcl, 25 mcg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J9190 Injection, fluorouracil, 500 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
A9573 Injection, gadopiclenol, 1 ml
J9045 Injection, carboplatin, 50 mg
84443 Blood test, thyroid stimulating hormone (tsh)
82378 Carcinoembryonic antigen (cea) protein level
J2405 Injection, ondansetron hydrochloride, per 1 mg
J9206 Injection, irinotecan, 20 mg
96372 Injection of drug or substance under skin or into muscle
88185 Flow cytometry technique for dna or cell analysis, each additional marker
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
82784 Gammaglobulin (immune system protein) measurement
85055 Reticulated (young) platelet measurement
84153 Psa (prostate specific antigen) measurement, total
J3489 Injection, zoledronic acid, 1 mg
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
71260 Ct scan of chest with contrast
96415 Administration of chemotherapy into vein, each additional hour
96523 Irrigation of implanted venous access drug delivery device
J1200 Injection, diphenhydramine hcl, up to 50 mg
81003 Automated urinalysis test
74177 Ct scan of abdomen and pelvis with contrast
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96417 Administration of additional new drug or substance into vein, 1 hour or less
J9060 Injection, cisplatin, powder or solution, 10 mg
96375 Injection of additional new drug or substance into vein
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
J3490 Unclassified drugs
85045 Red blood count, automated test
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
82565 Blood creatinine level
36591 Collection of blood sample from implanted device
J3475 Injection, magnesium sulfate, per 500 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
J7030 Infusion, normal saline solution , 1000 cc
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96361 Infusion into a vein for hydration, each additional hour
82044 Urine microalbumin (protein) analysis
96411 Administration of additional new drug or substance into vein using push technique
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
70553 Mri scan of brain before and after contrast
78816 Nuclear medicine study whole body with ct scan
81001 Manual urinalysis test with examination using microscope, automated
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
99441 Telephone medical discussion with physician, 5-10 minutes
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
71046 X-ray of chest, 2 views
71250 Ct scan of chest without contrast
96360 Infusion into a vein for hydration, 31-60 minutes
99442 Telephone medical discussion with physician, 11-20 minutes
74176 Ct scan of abdomen and pelvis without contrast
A9560 Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries
78306 Nuclear medicine study of bone and/or joint whole body
88184 Flow cytometry technique for dna or cell analysis, first marker
85610 Blood test, clotting time

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.